RPS6KB1 and glioblastoma: Moreover, higher levels of CCT4, mLST8, and activated S6K1 predicted a poor survival, similarly to YB-1 (Figure 8, I–K), implying that YB-1 may serve as a promising target for the treatment of glioblastoma.